🇺🇸 FDA
Patent

US 9526769

Macrocylic oximyl hepatitis C protease inhibitors

granted A61KA61K38/21A61K38/212

Quick answer

US patent 9526769 (Macrocylic oximyl hepatitis C protease inhibitors) held by Enanta Pharmaceuticals, Inc. expires Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Enanta Pharmaceuticals, Inc.
Grant date
Tue Dec 27 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 22 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61K, A61K38/21, A61K38/212, A61K38/215, A61K38/45